Bile Duct Cancer Therapy
Explore Appleglc.com’s bile duct cancer hub featuring futibatinib, pemigatinib, and durvalumab-based regimens — precision oncology resources for intrahepatic and extrahepatic cholangiocarcinoma patients.
Imfinzi
Durvalumab
Keytruda
Pembrolizumab
Opdivo
Nivolumab
Pemazyre
Pemigatinib
Lytgobi
Futibatinib
Truseltiq
Infigratinib
Balversa
Erdafitinib
Gemzar
Gemcitabine Hydrochloride
Platinol
Cisplatin
Paraplatin
Carboplatin
Xeloda
Capecitabine
Eloxatin
Oxaliplatin
Abraxane
Paclitaxel Protein-Bound Particles
Taxotere
Docetaxel
Camptosar
Irinotecan Hydrochloride
Avastin
Bevacizumab
Cyramza
Ramucirumab
Erbitux
Cetuximab
Lonsurf
Trifluridine and Tipiracil Hydrochloride
Stivarga
Regorafenib
Tecentriq
Atezolizumab
Bavencio
Avelumab
Libtayo
Cemiplimab-rwlc
Loqtorzi
Toripalimab-tpzi
Tevimbra
Tislelizumab-jsgr
Mvasi
Bevacizumab-awwb
Zirabev
Bevacizumab-bvzr
Nivolumab SC
Nivolumab and Hyaluronidase-nvhy
Pembrolizumab IV
Pembrolizumab
Durvalumab IV
Durvalumab
Rozlytrek
Entrectinib
Vitrakvi
Larotrectinib Sulfate
Retevmo
Selpercatinib
Gavreto
Pralsetinib
Tabrecta
Capmatinib
Tepmetko
Tepotinib
Krazati
Adagrasib
Lumakras
Sotorasib
Rybrevant
Amivantamab-vmjw
Augtyro
Repotrectinib